Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.

Hua, Lu; Hu, Baoying; Yan, Daliang; Liu, Jinxia; Shen, Yifen; Zhao, Fengbo; Shen, Chaoyan; Chen, Buyou; Cui, Xiaopeng

Hua, Lu; Hu, Baoying; Yan, Daliang; Liu, Jinxia; Shen, Yifen; Zhao, Fengbo; Shen, Chaoyan; Chen, Buyou; Cui, Xiaopeng.

Afiliação

Hua L; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China.
Hu B; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China; Basic Medical Research Centre, Medical College, Nantong University, Nantong, 226001, Jiangsu Province, China.
Yan D; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China.
Liu J; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China.
Shen Y; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China.
Zhao F; Basic Medical Research Centre, Medical College, Nantong University, Nantong, 226001, Jiangsu Province, China.
Shen C; Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, Jiangsu Province, China.
Chen B; Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China. Electronic address: chenbuyou1954@163.com.
Cui X; Department of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China. Electronic address: ntcuixiaopeng@163.com.

Pathol Res Pract ; 213(6): 688-697, 2017 Jun.

Article em En | MEDLINE | ID: mdl-28476378

Assuntos

Antineoplásicos/uso terapêutico; Carcinoma Hepatocelular/metabolismo; Resistencia a Medicamentos Antineoplásicos/fisiologia; Proteínas de Ligação ao GTP/metabolismo; Neoplasias Hepáticas/metabolismo; Niacinamida/análogos & derivados; Proteínas Nucleares/metabolismo; Compostos de Fenilureia/uso terapêutico; Adulto; Idoso; Antineoplásicos/farmacologia; Apoptose/efeitos dos fármacos; Carcinoma Hepatocelular/tratamento farmacológico; Carcinoma Hepatocelular/mortalidade; Carcinoma Hepatocelular/patologia; Linhagem Celular Tumoral; Feminino; Humanos; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/mortalidade; Neoplasias Hepáticas/patologia; Masculino; Pessoa de Meia-Idade; Niacinamida/farmacologia; Niacinamida/uso terapêutico; Compostos de Fenilureia/farmacologia; Prognóstico; Proteínas Proto-Oncogênicas c-bcl-2/metabolismo; Sorafenibe; Taxa de Sobrevida; Regulação para Cima; Adulto Jovem; Proteína X Associada a bcl-2/metabolismo

Palavras-chave

Hepatocellular carcinoma; Nucleostemin/GNL3; Prognosis; Sorafenib resistance; p53

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Proteínas Nucleares / Niacinamida / Carcinoma Hepatocelular / Resistencia a Medicamentos Antineoplásicos / Proteínas de Ligação ao GTP / Neoplasias Hepáticas / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google